Abstract
The genes of nuclear factor of activated T-cells ( NFATC ) play a key role both in heart valves formation and immune response. The genes belong to transcriptional factors and lead to myocardial hypertrophy in postnatal period that is confirmed by experimental models on animals. The purpose of this study was to reveale NFATC1 and NFATC4 genes expression level in the blood of 30 children with congenital heart diseases (CHD), 15 of them had bicuspid aortic valve, 15 had CHD without valve anomalies and 15 healthy children of the control group. No patients had signs of heart failure. At the first sage of Doppler heart ultrasound study a significant increase of the left ventricle posterior wall and ventricular septum thickness in comparison with CHD and control was revealed in BAV group. At the second stage a significant rise of relative normalized expression of NFATC1 in BAV children compared to CHD and control without differences in the expression of NFATC4 gene were established. Thus, in children with bicuspid aortic valve, formation of early myocardial hypertrophy with changes in nuclear factor of activated T-cells genes expression with prevailing of NFATC1 expression takes place. The detection of NFATC1 expression level in the blood of children could be considered as an early marker of progressive myocardial hypertrophy.
Highlights
Ɂɚɩɨɪɿɡɶɤɢɣ ɞɟɪɠɚɜɧɢɣ ɦɟɞɢɱɧɢɣ ɭɧɿɜɟɪɫɢɬɟɬ ɤɚɮɟɞɪɚ ɝɨɫɩɿɬɚɥɶɧɨʀ ɩɟɞɿɚɬɪɿʀ ɤɚɮɟɞɪɚ ɦɿɤɪɨɛɿɨɥɨɝɿʀ, ɜɿɪɭɫɨɥɨɝɿʀ ɬɚ ɿɦɭɧɨɥɨɝɿʀ * ɤɚɮɟɞɪɚ ɩɪɨɩɟɞɟɜɬɢɤɢ ɞɢɬɹɱɢɯ ɯɜɨɪɨɛ ** ɩɪ
The genes belong to transcriptional factors and lead to myocardial hypertrophy in postnatal period that is confirmed by experimental models on animals
The purpose of this study was to reveale 1)$7& and 1)$7& genes expression level in the blood of 30 children with congenital heart diseases (CHD), 15 of them had bicuspid aortic valve, 15 had CHD without valve anomalies and 15 healthy children of the control group
Summary
Ɐɟɥɶɸ ɞɚɧɧɨɝɨ ɢɫɫɥɟɞɨɜɚɧɢɹ ɫɬɚɥɨ ɨɩɪɟɞɟɥɟɧɢɟ ɭɪɨɜɧɹ ɷɤɫɩɪɟɫɫɢɢ ɝɟɧɨɜ NFATC1 ɢ NFATC4 ɜ ɤɪɨɜɢ 30 ɞɟɬɟɣ ɫ ɜɪɨɠɞɟɧɧɵɦɢ ɩɨɪɨɤɚɦɢ ɫɟɪɞɰɚ (ȼɉɋ). Ɇɚ ɩɟɪɜɨɦ ɷɬɚɩɟ ɢɫɫɥɟɞɨɜɚɧɢɹ ɦɟɬɨɞɨɦ ɞɨɩɩɥɟɪɷɯɨɤɚɪɞɢɨɝɪɚɮɢɢ ɭ ɞɟɬɟɣ ɫ ȾȺɄ ɜ ɫɪɚɜɧɟɧɢɢ ɫ ȼɉɋ ɛɟɡ ɤɥɚɩɚɧɧɵɯ ɚɧɨɦɚɥɢɣ ɢ ɝɪɭɩɩɨɣ ɤɨɧɬɪɨɥɹ ɛɵɥɨ ɜɵɹɜɥɟɧɨ ɞɨɫɬɨɜɟɪɧɨɟ ɭɬɨɥɳɟɧɢɟ ɡɚɞɧɟɣ ɫɬɟɧɤɢ ɥɟɜɨɝɨ ɠɟɥɭɞɨɱɤɚ ɢ ɦɟɠɠɟɥɭɞɨɱɤɨɜɨɣ ɩɟɪɟɝɨɪɨɞɤɢ. Ɇɚ ɜɬɨɪɨɦ ɷɬɚɩɟ ɢɫɫɥɟɞɨɜɚɧɢɹ ɛɵɥɨ ɜɵɹɜɥɟɧɨ ɞɨɫɬɨɜɟɪɧɨɟ ɭɜɟɥɢɱɟɧɢɟ ɨɬɧɨɫɢɬɟɥɶɧɨɣ ɧɨɪɦɚɥɢɡɨɜɚɧɧɨɣ ɷɤɫɩɪɟɫɫɢɢ ɝɟɧɚ NFATC1 ɭ ɛɨɥɶɧɵɯ ɫ ȾȺɄ ɩɪɢ ɨɬɫɭɬɫɬɜɢɢ ɞɨɫɬɨɜɟɪɧɵɯ ɪɚɡɥɢɱɢɣ ɜ ɭɪɨɜɧɟ ɷɤɫɩɪɟɫɫɢɢ ɝɟɧɚ NFATC4 ɜ ɭɤɚɡɚɧɧɵɯ ɤɚɬɟɝɨɪɢɣ ɞɟɬɟɣ. ɭ ɞɟɬɟɣ ɫ ɞɜɭɯɫɬɜɨɪɱɚɬɵɦ ɚɨɪɬɚɥɶɧɵɦ ɤɥɚɩɚɧɨɦ ɫɟɪɞɰɚ ɢɦɟɟɬ ɦɟɫɬɨ ɮɨɪɦɢɪɨɜɚɧɢɟ ɪɚɧɧɟɣ ɝɢɩɟɪɬɪɨɮɢɢ ɦɢɨɤɚɪɞɚ ɫ ɢɡɦɟɧɟɧɢɟɦ ɷɤɫɩɪɟɫɫɢɢ ɝɟɧɨɜ ɧɭɤɥɟɚɪɧɨɝɨ ɮɚɤɬɨɪɚ ɚɤɬɢɜɢɪɨɜɚɧɧɵɯ Ɍ-ɤɥɟɬɨɤ ɩɪɢ ɩɪɟɜɚɥɢɪɨɜɚɧɢɢ ɷɤɫɩɪɟɫɫɢɢ NFATC1. Ɉɩɪɟɞɟɥɟɧɢɟ ɭɪɨɜɧɹ ɷɤɫɩɪɟɫɫɢɢ ɭɤɚɡɚɧɧɵɯ ɝɟɧɨɜ ɜ ɤɪɨɜɢ ɞɟɬɟɣ ɫ ȾȺɄ ɦɨɠɟɬ ɪɚɫɫɦɚɬɪɢɜɚɬɶɫɹ ɤɚɤ ɪɚɧɧɢɣ ɦɚɪɤɟɪ ɩɪɨɝɪɟɫɫɢɪɭɸɳɟɣ ɝɢɩɟɪɬɪɨɮɢɢ ɦɢɨɤɚɪɞɚ
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
